Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1.
The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors.
In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
| Country | Netherlands |
| Founded | 2003 |
| IPO Date | May 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 321 |
| CEO | Jan van de Winkel |
Contact Details
Address: Uppsalalaan 17, 3rd & 4th floor Utrecht, 3584 CT Netherlands | |
| Phone | 31 30 253 8800 |
| Website | merus.nl |
Stock Details
| Ticker Symbol | MRUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651311 |
| CUSIP Number | N5749R100 |
| ISIN Number | NL0011606264 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Chief Executive Officer and Executive Director |
| Gregory D. Perry | Chief Financial Officer |
| Peter B. Silverman J.D. | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal |
| Dr. Fabian Zohren M.D., Ph.D. | Chief Medical Officer |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Cornelis Adriaan de Kruif Ph.D. | Chief Technology Officer and Executive Vice President |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer and Senior Vice President |
| Sherri Spear | Senior Vice President of Investor Relations and Strategic Communications |
| Kathleen Farren | Director of IR and Corporate Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2025 | SCHEDULE 13D/A | Filing |
| Dec 30, 2025 | 25-NSE/A | Filing |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 30, 2025 | SC 14D9/A | Filing |
| Dec 30, 2025 | SC TO-T/A | Filing |
| Dec 19, 2025 | SCHEDULE 13D | Filing |
| Dec 12, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 12, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 12, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 12, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |